Factors Associated With Mortality in 2-Year Survivors of Head and Neck Cancer

Abstract

In addition to older age and advanced stage, pain, poor overall quality of life, and tobacco use 2 years after diagnosis characterize patients who might need longer and more intense follow-up care to improve their observed and disease-specific survival. This information is useful in developing management plans for patients transitioning from a focus on cancer surveillance into survivorship.

Empirical comparison of routinely collected electronic health record data for head and neck cancer‐specific survival in machine‐learnt prognostic models

“…Older age and tobacco smoking have previously been shown to increase the risk of death with HNC within 2 years in one study by Thompson et al 24 ; however, this was not evident in our study, even when age was assessed as a dichotomous or continuous variable and with complete data in the research dataset. This is likely due to the statistical univariate cut‐off used in our study ( p < 0.05) compared to Thompson et al ( p ≤ 0.10), meaning tobacco smoking was not included in our multivariate model.…”

DIRC3 and near NABP1 genetic polymorphisms are associated laryngeal squamous cell carcinoma patient survival

“…In some researches indicated that patients T-stage and N-stage had demonstrated to be significantly associated with survival and these findings are consistent with results of most other studies. Our study also obtained the consistent conclusion [9, 13, 14]. A multivariate analysis was conducted, taking the variables found to be significant in univariate analyses ( p ≤0.2) into account.…”

Machine Learning and Nomogram Prognostic Modeling for 2-Year Head and Neck Cancer–Specific Survival Using Electronic Health Record Data: A Multisite Study

“…Multivariable analysis identified age, tumor site, T and N classification, and EQD2T as predictors of 2-year CSS. A 1-year increase in age increased the risk of death by 1%-5% by tumor site, comparable with the 7% increased risk reported by Thompson et al 33 in a cohort of patients with HNC diagnosed between 2001 and 2008 at a single tertiary US institution; however, uncertainty around the eligibility criteria makes definitive comparisons with our study difficult. Stage is a strong prognostic factor in HNC.…”